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Delayed graft function is an early complication following kidney transplantation with an unclear molecular mechanism. Here we
determined whether impaired reactive aldehyde metabolism is associated with delayed graft function. Human kidney biopsies from
grafts with delayed graft function were compared with grafts that did not develop delayed graft function by Ingenuity gene pathway
analysis. A second series of grafts with delayed graft function (n = 10) were compared to grafts that did not develop delayed graft
function (n = 10) by measuring reactive aldehyde metabolism, reactive aldehyde-induced protein adduct formation, and aldehyde
dehydrogenase (ALDH) gene and protein expression. In the ﬁrst series of kidney biopsies, several gene families known for
metabolizing reactive aldehydes, such as aldehyde dehydrogenase (ALDH), aldo-keto reductase (AKR), and glutathione-S
transferase (GSTA), were upregulated in kidneys that did not develop delayed graft function versus those that did. In the second
series of kidney grafts, we focused on measuring aldehyde-induced protein adducts and ALDH enzymatic activity. The reactive
aldehyde metabolism by ALDH enzymes was reduced in kidneys with delayed graft function compared to those that did not
(37± 12∗ vs. 79± 5 μg/min/mg tissue, ∗P < 0 005, respectively). ALDH enzymatic activity was also negatively correlated with
length of hospital stay after a kidney transplant. Together, our study identiﬁes a reduced ALDH enzymatic activity with kidneys
developing delayed graft function compared to those that did not. Measuring ALDH enzymatic activity and reactive aldehyde-
induced protein adducts can potentially be further developed as a biomarker to assess for delayed graft function and recovery
from a kidney transplant.
1. Introduction
Organ transplantation, including kidney transplantation, is a
known and planned occurrence of organ reperfusion injury.
Reperfusion injury in turn can trigger delayed graft function,
resulting in the deferred functional recovery of the donor
kidney following kidney transplantation.
Delayed graft function detrimentally aﬀects renal func-
tion and graft longevity and is a risk factor for acute kidney
rejection [1, 2]. The incidence of delayed graft function in
deceased donor kidneys is ~25% and perhaps as high as
50% for kidneys from cardiac death donor organs [3, 4].
Additionally, the incidence of delayed graft function is
steadily rising due to the increased use of marginal donor
grafts secondary to organ transplant shortages. As a conse-
quence, delayed graft function leads to reduced graft func-
tion, prolonged hospital admissions, increased demand of
donor kidneys for retransplantation secondary to rejection,
and a higher economic societal burden [5]. Several deﬁni-
tions exist for delayed graft function [6]. For this manu-
script, we deﬁne delayed graft function as the requirement
of dialysis within the ﬁrst 7 postoperative days of a kidney
transplant [6].
During reperfusion of an organ, reactive oxygen spe-
cies produced at the mitochondria causes lipid peroxidation
which generates reactive aldehydes which can impair cellular
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functions [7–9]. The reactive aldehydes produced include acet-
aldehyde, malondialdehyde (MDA), and 4-hydroxynonenal
(4-HNE). To metabolize these reactive aldehydes, several
protein families such as glutathione-S reductase, aldo-keto
reductase, and aldehyde dehydrogenase gene families con-
tribute to metabolizing aldehydes produced within the cell
[7, 10, 11].
Although kidney transplants from living donors are less
susceptible to delayed graft function when compared to
grafts from deceased donors [1], the diﬀerences in molecular
biology have not been extensively studied. Here we used
human renal biopsies from transplanted deceased donor kid-
neys who developed delayed graft function and compared the
molecular diﬀerences using gene arrays to kidneys from liv-
ing donor transplants that did not develop delayed graft
function. From this approach, we here suggest that impaired
reactive aldehyde metabolism by ALDH enzymes is associ-
ated with delayed graft function.
2. Materials and Methods
2.1. Patient Enrollment. The study protocol was approved
by the medical ethics committee at the Leiden University
Medical Center. Written informed consent was obtained
from each patient.
Paired renal cortical biopsies were obtained at the end of
the cold ischemic period (prior to implantation) and 45min
after reperfusion of the kidney in the recipient. Kidney biop-
sies from an initial 18 donor kidneys were used to conduct
the whole genome array portion of the study (Figure 1(a)).
We then obtained an additional 10 paired renal biopsies from
living donor kidneys that did not develop delayed graft func-
tion and 10 paired renal biopsies from deceased donor kid-
neys that developed delayed graft function. Details regarding
enrollment and patient demographics are described in detail
(Tables 1 and 2).
Renal allografts were perfused and stored with either
University of Wisconsin solution or Custodiol® HTK (his-
tidine–tryptophan–ketoglutarate) solution. None of the
grafts were machine perfused. For renal transplantation,
all patients were induced by propofol, sufentanil, and atra-
curium. Patients were intubated in addition to a central
venous catheter used for intraoperative monitoring.
Patients received basiliximab (day 0 and 4) as immunosup-
pressive induction. Patients were maintained on tacrolimus
or cyclosporine A, mycophenolate mofetil, and steroids for
immunosuppression.
Biopsies were taken from the upper pole of the kidney.
For biopsies taken after reperfusion, a spring-loaded auto-
matic biopsy needle was used (16Ga Travenol). Tissue was
snap frozen in liquid nitrogen and stored at −80°C and
labeled with a unique identiﬁer, blinding the person perform-
ing the analysis. For the genome array studies, all samples
were analyzed together after the groups were collected. The
validation studies were also performed after the tissue was
obtained, selectively using only tissue from deceased donors
who developed delayed graft function after transplantation.
The transplanted patients were also followed during their
hospital stay. The length of hospital stay after transplantation
in addition to glomerular ﬁltration rate at postoperative day 7
was also assessed. Patients were considered as developing
delayed graft function if they were in need of dialysis within
the ﬁrst week after transplantation. For those requiring dial-
ysis, acute rejection was excluded as a cause of delayed graft
function by renal biopsy. Surgical complications of the trans-
plant procedure were also excluded as a source of delayed
graft function. Further, if transplant recipients required one
episode of dialysis after transplantation due to incident
hyperkalemia, these grafts were also not included as having
delayed graft function.
2.2. Genome Array. Paired biopsies were taken for the
patients undergoing renal transplantation with one biopsy
prior to transplantation and one biopsy 45 minutes after
transplant reperfusion. From these renal biopsies, total
RNA was extracted using RNAzol (Campro Scientiﬁc, Vee-
nendaal, Netherlands) and glass beads. The integrity of each
RNA sample was examined by Agilent Lab-on-a-chip tech-
nology using the RNA 6000 Nano LabChip kit and a Bioana-
lyzer 2100 (Agilent Technologies, Amstelveen, Netherlands).
RNA preparations were considered suitable for array hybrid-
ization only if samples showed intact 18S and 28S rRNA
bands and displayed no chromosomal peaks or RNA degra-
dation products (RNA integrity number >8.0). Microarray
analysis was performed using Illumina whole-genome gene
expression BeadChips (Illumina BeadArray®, San Diego,
USA) according to the manufacturer’s instructions at the Ser-
vice XS facility in Leiden.
The tissue biopsies collected from the two groups were
run on separate gene arrays. The 2 paired tissue biopsies
obtained for each transplanted kidney resulted in running
36 gene arrays for the tissue biopsies that were collected.
The gene arrays obtained were analyzed by a statistician at
the University of Leiden blinded to the identiﬁcation of the
groups of tissue biopsies collected. An average replicate value
was calculated and log2 ratios were computed by comparing
the matched pair biopsies and the gene expression diﬀerences
for each transplanted kidney prior to and after reperfusion.
One value per gene was calculated for the average expression
of multiple probes with the same Entrez gene identiﬁcation,
resulting in 15,093 unique gene proﬁles. The unique gene
proﬁles obtained from the whole genome array were ana-
lyzed by Ingenuity pathway analysis (Redwood City, CA,
USA).
2.3. Biochemical Assays. In addition to biopsies collected for
gene array studies, 20 transplanted kidneys were used to per-
form further biochemical analysis which included qPCR,
western blot (for aldehyde-induced protein adduct and pro-
tein expression), and aldehyde enzymatic activity assays.
For qPCR, RNA was isolated from kidney biopsies taken
at the end of the cold ischemic period. Kidney biopsy lysates
were made by soniﬁcation, and RNA was isolated by the use
of Ambion© RNAqueous Kit. To substantially reduce the
possibility of DNA contamination in the preparations, the
isolated total RNA was subject to precipitation with lithium
chloride and DNase digestion (Ambion DNase-free). cDNA
was made using the Takara© Primescript cDNA synthesis
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kit with oligo dT primers. qPCR reactions were performed in
a ﬁnal volume of 20μl that contained 15μl of Fast SYBR©
Green Master Mix (Life Technologies), 1000 nM primer
(ALDH2, ALDH7A1, or GAPDH) or 500nM primer
(ALDH4A1), and 10ng cDNA. The cycling protocol was 20
seconds at 95°C, followed by 40 cycles of 3 seconds at 95°C
and 30 seconds at 61°C. The melt curve protocol was 15 sec-
onds at 95°C, followed by a minute at 60°C, followed by a
gradual temperature increase from 60°C to 95°C (+0.03°C
per 15 seconds) in 42 minutes.
Western blot analysis was used to quantify 4-HNE-
induced protein adducts in addition to protein expression
of ALDH enzymes. For western blot analysis, kidney biopsies
taken 45 minutes after reperfusion were homogenized in
mannitol-sucrose buﬀer (210mM mannitol, 70mM sucrose,
MOPS 5mM, and EDTA 1mM, pH7.4) with protease and
phosphatase inhibitors (1 : 300, Sigma protease inhibitor
cocktail, Sigma phosphatase inhibitor cocktail 2, and phos-
phatase inhibitor cocktail 3) using a glass homogenizer
(Wheaton, 1mL tissue grinder). Homogenates were subse-
quently collected and spun at 800 g× 10 minutes to remove
nuclei and debris. The supernatant was collected and protein
counts were obtained by Bradford assay and samples were
normalized to μg protein. Western blot was performed as
described [12]. Primary antibodies used included anti-
4HNE (rabbit, Alpha Diagnostics, 1 : 500), ALDH2 (goat,
Santa Cruz, 1 : 1000), ALDH4A1 (rabbit, Abcam #EPR14287,
1 : 1000), ALDH7A1 (rabbit, Abcam, #EP1934Y, 1 : 1000),
and ALDH1A1 (rabbit, Abcam, #EP1993Y, 1 : 1000). Second-
ary antibodies were used at 1 : 3000 consisting of anti-goat
(Santa Cruz) and anti-rabbit (Sigma). Density of bands was
measured by ImageJ and normalized to GAPDH (Santa
Cruz, #47724, 1 : 3000).
To determine ALDH enzyme activity, 25μg of protein
were used. ALDH enzyme activity was measured spectropho-
tometrically (340 nm) by analyzing the reaction of NAD+ to
NADH as previously described [7, 12]. The activity assay was
performed at 25°C in 50mM sodium pyrophosphate buﬀer
(pH9.4), 2.5mM NAD+, and 10mM acetaldehyde was used
as substrate. ALDH enzyme activity was converted to μmole
NADH/min/mg of protein.
2.4. Statistical Analysis. Sample sizes were chosen for this
study based on previous experience the University of Leiden
has on conducting clinical studies regarding ischemia-
reperfusion injury in human kidney transplantation [13,
14]. SPSS 22.0 (SPSS, Chicago, IL) was used for gene array
statistical analysis. For pathway analysis, data is represented
as P values for the change in expression comparing the paired
biopsies, ﬁtting into predeﬁned pathways. P values are
expressed as the –log P value. Results were then analyzed
by biostatistical methods using average replicate values for
each group of samples. Log2 ratios were computed and one
value per gene was calculated for the average expression of
probes with the same Entrez gene ID. For qPCR and protein
assays, data was analyzed with GraphPad prism.
3. Results
Changes in gene pathway p-values using Ingenuity pathway
analysis were calculated and initially reported [15]. Here,
we analyzed the gene array data by comparing the gene array
of a biopsy taken 45 minutes after reperfusion compared to
the paired biopsy gene array taken at the end of cold ische-
mia. When looking at these diﬀerences for each group, we
identiﬁed 10 signaling pathways that were induced with the
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Figure 1: Changes in ALDH enzymes found by gene array studies. (a) Experimental scheme for biopsies. 10 paired renal biopsies from
kidneys that did not develop delayed graft function and 8 paired renal biopsies that developed delayed graft function were obtained. One
biopsy was taken prior to transplant at the end of cold ischemia. The second biopsy was taken after transplant and reperfusion 45 minutes
after the cross-clamp was removed. (b) Of the genes identiﬁed by Ingenuity pathway analysis, several gene families are identiﬁed to be
involved in reactive aldehyde metabolism. (c), (d) ALDH2 and ALDH7A1 were statistically signiﬁcant between kidneys that did not
develop delayed graft function compared to kidneys developing delayed graft function (∗P < 0 01). (e) ALDH4A1 nearly reached statistical
signiﬁcance (#P = 0 05). (f) ALDH1A1, another ALDH family member, did not change between living donor kidneys compared to kidneys
that developed delayed graft function. (-) = donor kidneys without delayed graft function; (+) = donor kidneys with delayed graft function.
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highest diﬀerences in p-values in kidneys which did not
develop delayed graft function compared to the kidneys
which developed delayed graft function (Table 3). In particu-
lar, when examining these diﬀerences, distinct genes were
upregulated for only the kidney biopsies that did not develop
delayed graft function at reperfusion when compared to the
kidney biopsies that developed delayed graft function for
these pathways (Table 3).
Genes that contribute to aldehyde metabolism were
identiﬁed in this gene array including the family of aldehyde
dehydrogenaseenzymes(ALDH2,ALDH4A1,andALDH7A1),
aldo-keto reductases (AKR1A1), andglutathione-S-transferases
(GSTA1, GSTA2, GSTA3, and GST5) known to metabolize
reactive aldehydes typically generated by the mitochondria
during reperfusion (Figure 1(b)). Together, these results sug-
gest that diﬀerences exist in the reactive aldehyde produc-
tion and metabolism within donor kidneys that developed
delayed graft function versus those that did not.
We further examined the gene array expression for
ALDH2, ALDH4A1, and ALDH7A1 in addition to the other
ALDH family of enzymes. Other ALDH enzymes (besides
the cytosolic enzymes ALDH3A2 and ALDH1L1 unknown
to be involved in aldehyde metabolism) remained unchanged
(Supplemental Figure 1). ALDH2 and ALDH7A1 were
signiﬁcantly higher in the living donor grafts compared to
the grafts with delayed graft function (ALDH2: 1919.4± 86.7
Table 1: Patient characteristics for gene array studies.
Living donor
kidney transplant
(n = 10)
Deceased donor
kidney transplant
(n = 8)
Age of recipient (yrs) 49± 5 56± 4
Sex of recipient (% males) 60% 50%
Age of donor (yrs) 52± 2 49± 6
Sex of donor (% males) 30% 75%
Cold ischemia time (min) 213± 12 1001± 96∗
Hospital stay (days) 8± 1 15± 2∗
Recipient cause of renal failure
Glomerulonephritis 40% 12.5%
Polycystic kidney disease 20% 25%
Diabetes mellitus type 2 10% 12.5%
Obstructive uropathy 10% 0%
Malignant hypertension 0% 0%
Renal failure 20% 50%
Donor cause of death
Living donor 100%
CVA 0%
SAB 25%
Trauma 37.5%
CA-OHCA-AMI 25%
Suicide 0%
Miscellaneous 12.5%
Histocompatibility (HLA mismatches, %)
0 10% 12.5%
1 10% 25%
2 10% 25%
3 20% 25%
4 20% 12.5%
5 20% 0%
6 10% 0%
A total of 18 patients were included. When comparing recipients of a living
donor transplant to recipients of a deceased donor transplant, signiﬁcant
diﬀerences were noted for duration of ischemia time, and length of
posttransplantation hospital stay. ∗P < 0 01, CVA = cerebral vascular
accident, SAB = subarachnoid bleeding, CA = cardiac arrest, OHCA= out
of hospital cardiac arrest, AMI = acute myocardial infarction. Data
represents mean ± SEM.
Table 2: Patient characteristics for validation studies.
Living donor
kidney transplant
(n = 10)
Deceased donor
kidney transplant
(n = 10)
Age of recipient (yrs) 58± 4 56± 4
Sex of recipient (% males) 70% 60%
Age of donor (yrs) 58± 2 57± 4
Sex of donor (% males) 50% 70%
Cold ischemia time (min) 221± 18 900± 88∗
Hospital stay (days) 8± 2 15± 3∗
Recipient cause of renal failure
Glomerulonephritis 40% 30%
Polycystic kidney disease 20% 20%
Diabetes mellitus type 2 0% 20%
Obstructive uropathy 10% 10%
Malignant hypertension 10% 10%
Renal failure 20% 10%
Donor cause of death
Living donor 100%
CVA 20%
SAB 20%
Trauma 20%
CA-OHCA-AMI 30%
Suicide 10%
Miscellaneous 0%
Histocompatibility (HLA mismatches, %)
0 0% 10%
1 10% 10%
2 0% 30%
3 10% 40%
4 20% 0%
5 40% 10%
6 20% 0%
A total of 20 patients were recruited. When comparing recipients of a
living donor transplant to recipients of a deceased donor transplant,
signiﬁcant diﬀerences were noted for developing delayed graft function,
duration of ischemia, and length of posttransplantation hospital stay.
∗P < 0 01, CVA = cerebrovascular accident, SAB = subarachnoid bleeding,
CA = cardiac arrest, OHCA= out of hospital cardiac arrest, AMI = acute
myocardial infarction.
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versus 1314.5± 76.6∗, ALDH7A1: 1739.9± 65.5 versus
1230.4± 83.1∗, ∗P = 0 001) with ALDH4A1 just at statistical
signiﬁcance (1324.1± 34.7 versus 1102.9± 105.9; p = 0 05,
Figures 1(c)–1(e)). As a comparison, no diﬀerences were
seen for the cytosolic ALDH enzymeALDH1A1 (Figure 1(f)).
Since the gene array ﬁndings suggest a link to reactive
aldehyde metabolism, we further examined reactive aldehyde
metabolism and aldehyde-induced protein adducts by obtain-
ing paired biopsies from additional grafts that did not develop
delayed graft function and donor kidney grafts that developed
delayed graft function. For these biopsies, we determined the
ALDH-dependent enzymatic activity to metabolize reactive
aldehydes (using the substrate NAD+) in addition to 4-
hydroxynonenal- (4-HNE-) induced protein adducts for
biopsies taken 45 minutes after reperfusion. The total ALDH
enzymatic activity was signiﬁcantly higher for donor kidney
biopsies without delayed graft function when compared to
biopsies from kidneys that developed delayed graft function
(Figure 2(a): 78.6± 4.7 vs. 36.9± 11.5∗μg/min/mg protein, n
= 8/group, ∗P < 0 005). Additionally, the amount of 4-
hydroxynonenal-induced protein adducts in the reperfused
kidneys was signiﬁcantly higher for kidneys developing
delayed graft function versus those that did not (Figure 2(b),
4-HNE adducts: 1.2± 0.2 vs. 1.9± 0.3∗, n = 10/group, ∗P <
0 028, n = 10/group).
Since a full analysis of the ALDH, AKR, and GSTA
enzyme classes identiﬁed through gene array was not feasi-
ble to examine in human tissue biopsies based upon the
biopsy sample size, we chose 3 candidate genes from our
array that appeared in high frequency within the signaling
pathways. These members of the aldehyde dehydrogenase
gene family, ALDH2, ALDH7A1, and ALDH4A1, metabo-
lize reactive aldehydes in a NAD-dependent fashion and
can protect against cellular stress [7, 8, 16, 17]. Therefore,
we focused on examining expression for the ALDH enzymes
ALDH2, ALDH4A1, and ALDH7A1 with ALDH1A1 used
as a control.
We performed qPCR on all biopsy samples obtained
prior to kidney transplantation. The details of the primer
design and validation for ALDH2, ALDH4A1, ALDH7A1,
and ALDH1A1 are described (Figure 3(a) and Supplemental
Figure 2). Signiﬁcant diﬀerences were noted when calculating
Table 3: Gene array diﬀerences from living compared to deceased donor kidney biopsies.
Pathway
Diﬀerence
in value
Genes only upregulated in living donor
Genes only
upregulated in
deceased donor
Common
Serotonin degradation 6.59
ALDH4A1, ALDH2, ALDH7A1, ALDH3A2,
ADH6, UGT2B7, UGT2B10, UGT2A3,
UGT1A9, AKR1A1, SMOX, DHRS4
None None
Tryptophan degradation 5.54
ALDH4A1, ALDH2, ALDH7A1,
ALDH3A2, AKR1A1, DDC, SMOX
None None
Histamine degradation 5.34
ALDH4A1, ALDH2, ALDH7A1,
ALDH3A2, HNMT, ABP1
None None
Ethanol degradation II 5.03
ALDH4A1, ALDH2, ALDH7A1, ALDH3A2,
ADH6, AKR1A1, ACSS2, DHRS4
None None
NRF-2-mediated oxidative
stress response
4.82
AKR7A2, AKR1A1, FTL, NQO2, ABCC2, MAF,
GSTA5, SCARB1, FMO1, GSTA1, GSTA2, GSTA3,
MGST1, PRKCQ, ACTB, ACTG1, MGST2,
MAP2K3, SQSTM1, AOX1, EIF2AK3, EPHX1
UBB, JUNB,
DNAJA1, DNA
FOS, JUN, JUND,
DNAJA4, DNAJB11,
MAFF
Xenobiotic metabolism
signaling
4.63
ALDH4A1, ALDH7A1, ALDH3A2, ALDH8A1, FTL,
UGT2B7, NQO2, ABCC2, MAF, GSTA5, CYP3A7,
HS6ST2, SMOX, FMO1, GSTA1, GSTA2, GSTA3,
MGST1, PRKCQ, UGT2B10, UGT8, PPP2R5A,
MGST2, MAP2K3, EIF2AK3, UGT1A9
CITED2,
MAP3K8, TNF,
HSP90AB1,
HSP90AA1
None
Noradrenaline and
adrenaline degradation
4.33
ALDH4A1, ALDH2, ALDH7A1, ALDH3A2,
ALDH8A1, ADH6, AKR1A1, SMOX, DHRS4
None None
LPS/IL-1-mediated
inhibition of RXR function
4.14
ALDH4A1, ALDH7A1, ALDH3A2, ALDH8A1,
GSTA1, GSTA2, GSTA3, GSTA5, APOE, MGST1,
SLC27A2, ACOX2, ABCC2, CYP3A7, IL1R2,
MGST2, SCARB1, NR5A2, HS6ST2, FMO1, SMOX
ALAS1, HMGCS1,
TNF
ACSL3, JUN,
NR0B2
Glutathoine-mediated
detoxiﬁcation
4.12
GSTA1, GSTA2, GSTA3, GSTA5,
MGST1, MGST2, GGH
None None
Oxidative ethanol
degradation
3.98 ALDH4A1, ALDH2, ALDH7A1, ALDH3A2, ACSS2 None ACSL3
Whole genome array changes before and after kidney transplantation were compared from each donor kidney that did not develop delayed graft function
(living donor) with those that did develop delayed graft function (deceased donor) using Ingenuity pathway analysis. The diﬀerence in P-values between
gene arrays sets were the highest for the 10 signaling pathways listed. Speciﬁc genes that were only upregulated in living donor kidneys and deceased donor
kidneys are listed. Further, genes that were upregulated in both kidneys that developed delayed graft function versus those that did not are also listed.
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a delta Ct (normalized to GAPDH) for donor kidneys that
did not develop delayed graft function when compared to
those donor kidneys that developed delayed graft function
(Figures 3(b)–3(d), n = 10/group, ALDH2: 3.3± 0.8 vs. 5.7
± 0.8∗, ALDH7A1 3.7± 0.4 vs. 5.6± 0.6∗, and ALDH4A1:
2.5± 0.3 vs. 4.6± 0.6∗∗, ∗P < 0 01, ∗∗P < 0 001, reported as
delta Ct values normalized to GAPDH). As a comparison,
ALDH1A1 was unchanged (Figure 3(e)).
We also quantiﬁed the levels of protein expression by
western blot for ALDH2, ALDH7A1, and ALDH4A1. Both
ALDH7A1 and ALDH4A1 had signiﬁcant changes in protein
expression between the two groups (Figure 4(a), ALDH7A1:
1.2± 0.1∗ vs. 0.7± 0.07, ∗P < 0 001, Figure 4(b), ALDH4A1:
1.7± 0.3∗ vs. 0.9± 0.1, ∗P < 0 017). Western blot for ALDH2
also showed a relative change in expression that did not
reach statistical signiﬁcance (Figure 4(c), ALDH2: 5.2± 1.1
vs. 4.0± 0.6).
Since our results suggested that impaired reactive
aldehyde metabolism may be associated with delayed graft
function, we further examined whether cold ischemia times
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Figure 2: ALDH enzyme activity and 4-HNE protein-induced adduct formation taken from biopsies of kidneys 45 minutes after reperfusion.
(a) ALDH enzymatic activity when challenged with acetaldehyde. n = 8/group, ∗P < 0 005; (b) 4-hydroxynonenal-induced protein adducts.
Representative western blot in addition to quantiﬁcation by densitometry. Western blots were normalized to GAPDH. (-) = donor kidneys
without delayed graft function; (+) = donor kidneys with delayed graft function, n = 10/group, ∗P < 0 05.
Target Reverse primer
AAGGCCTTGTCCCCTTCAG
GCACAGATCCGAGTTGGGAA
CTGCAGTGATTGATGCCAAGTC
GCATTGTCCAAGTCGGCATC
AGTGATGGCATGGACTGTGG
Forward primer
CCGAGGTCTTCTGCAACCAG
CTTGCCCCCATAGACCACTG
GGTCCTTGCTCTCCACGATG
ATCAAAGAAGCTGCCGGGAA
GAGAAGGCTGGGGCTCATTT
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Figure 3: qPCR studies for kidney biopsies taken prior to transplant. For a separate series of kidney transplants, biopsies were collected for
qPCR. (a) PCR primers used for qPCR. qPCR reactions were performed in a ﬁnal volume of 20μl that contained 15μl of Fast SYBR© Green
Master Mix (Life Technologies), 1000 nM primer (ALDH2, ALDH7A1 or GAPDH) or 500 nM primer (ALDH4A1), and 10 ng cDNA. (b–e)
qPCR results for (b) ALDH2, (c) ALDH7A1, (d) ALDH4A1, and (e) ALDH1A1. ALDH2, ALDH7A1, and ALDH4A1 by qPCR were
signiﬁcantly elevated in kidneys that did not develop delayed graft function versus those kidneys that developed delayed graft function
(n = 10/group, ∗P < 0 05). Ct values of each gene were normalized to GAPDH to calculate the delta Ct value. (-) = donor kidneys without
delayed graft function; (+) = donor kidneys with delayed graft function.
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inﬂuenced ALDH enzymatic activity. Generally, the cold
ischemia times in the kidneys that did not develop delayed
graft function was less compared to the kidneys that devel-
oped delayed graft function (Table 2, living donor without
delayed graft function: 221± 18minutes versus deceased
donor with delayed graft function: 900± 88∗ minutes, ∗P <
0 01). No correlation between ALDH enzymatic activity
and cold ischemia times for living donor grafts without
delayed graft function was found, and the range of cold ische-
mia time for these kidneys was small (Figure 5(a) 6 of 8 sam-
ples had cold ischemia times between 210-240minutes).
Further, in grafts that did develop delayed graft function, a
wider range of cold ischemia times existed; however, no asso-
ciation between ALDH enzymatic activity and cold ischemia
times was found (Figure 5(b)).
However, ALDH enzymatic activity was also examined in
relation to glomerular ﬁltration rate (GFR) measured in
patients at postoperative day 7 and length of hospital stay.
Interestingly, those kidney biopsies that had lower ALDH
enzymatic activity also had a lower GFR at day 7 (Figure 5(c):
GFR <10: 30± 12∗, GFR 10-60: 49± 25, GFR >60: 79± 5μg/
min/mg protein, n = 5, n = 3, and n = 8, respectively, ∗P =
0 013 vs. GFR >60 group). In addition, an inverse associa-
tion also existed with ALDH enzymatic activity when com-
pared to the length of hospital stay (Figure 5(d): r = −0 58
by Pearson coeﬃcient, P = 0 0183).
4. Discussion
Here we describe an important role by enzymes within the
human kidney to metabolize reactive aldehydes produced
during reperfusion of an organ transplant. We suggest
quantifying the enzymatic activity to metabolize reactive
aldehydes coupled with reactive aldehyde-induced protein
adduct levels may be useful in possibly predicting delayed
graft function and recovery from a kidney transplant. Our
results suggest that measuring the overall reactive aldehyde
balance within the donor kidney may be important in
understanding which transplants may be at risk for
developing delayed graft function. These initial ﬁndings
may potentially lead to developing a cellular biomarker
based on reactive aldehyde production and metabolism to
predict delayed graft function.
Presently, several biomarkers are being investigated for
their ability to predict delayed graft function including
neutrophil gelatinase-associated lipocalin (NGAL), kidney
injury molecule 1 (KIM-1), interleukin18 (IL-18), klotho,
cystatin C, and liver type fatty acid binding protein (L-
FABP) [18–20]. Recently, NGAL blood levels taken from
brain-dead kidney donors prior to kidney graft harvesting
could not predict the development of delayed graft function
[20]. Additionally, the idea of combining several biomarkers
to detect delayed graft function was proposed, with a possible
triple biomarker approach of serum malondialdehyde, cysta-
tin C, and creatinine [21].
Although associations exist between serum malondial-
dehyde levels and delayed graft function [21, 22], serum
malondialdehyde may underestimate the cellular damage
contributed to lipid peroxidation. This is since ~95% of
malondialdehyde is in the bound form with only 5% being
free to measure in the serum for patients with end-stage renal
disease [23]. Therefore, assessing both reactive aldehyde-
induced protein levels and reactive aldehyde metabolism
may provide a means to develop complementary biomarkers
in order to predict delayed graft function. Even though our
results were from kidney biopsies and not measured from cir-
culating blood levels, we suggest that measuring the state of
reactive aldehyde production and metabolism may poten-
tially be useful in predicting delayed graft function rather
than assessing speciﬁc protein biomarkers or reactive alde-
hyde levels within the blood.
Our data also examined ALDH7A1, ALDH4A1, and
ALDH2 within the ALDH enzyme family suggesting that
these enzymes are involved and contribute to a decreased
reactive aldehyde metabolism seen in kidneys developing
delayed graft function. However, the contribution of other
families of enzymes such as AKR and GSTA cannot be
excluded. Although protein expression was not signiﬁcantly
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Figure 4: Western blot of ALDH7A1, ALDH4A1, and ALDH2 taken from biopsies of kidneys 45 minutes after reperfusion. (a–c) Western
blots for (a) ALDH7A1, (b) ALDH4A1, and (c) ALDH2. All western blots were normalized to GAPDH. Both ALDH7A1 and ALDH4A1 were
signiﬁcantly diﬀerent in kidneys that did not develop delayed graft function versus those kidneys that developed delayed graft function.
(-) = donor kidneys without delayed graft function; (+) = donor kidneys with delayed graft function, n = 10/group, ∗P < 0 05.
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changed for ALDH2 in our study, it cannot be ruled out that
ALDH2 was posttranslationally modiﬁed by reactive alde-
hydes. To identify posttranslational modiﬁcations, immuno-
precipitation of an enzyme (such as ALDH2) followed by
western blot for aldehyde-induced protein adducts could be
performed. However, the amount of protein needed to con-
duct this type of study exceeded the amount obtained from
a renal biopsy for our study. Based upon prior studies per-
formed in vitro, 4-HNE can inhibit human recombinant
ALDH2 resulting in a decreased capability for the enzyme
to metabolize reactive aldehydes [24]. At 50 μM 4-HNE,
most of the eﬀect is reversible; however, at 500 μM 4-HNE
concentrations, this eﬀect is noted to be irreversible [24].
Since with increases in oxidative stress blood levels of 4-
HNE in humans can increase 10- to 100-fold [25], the reac-
tive aldehydes generated during kidney reperfusion likely
can cause a partial inhibition of ALDH enzymes. This inhibi-
tion can potentially contribute to the decreased reactive alde-
hyde metabolism we identiﬁed for our study in kidneys that
developed delayed graft function.
In the era of precision medicine, it is also important to
determine how genetic polymorphisms in mitochondrial
ALDH enzymes may aﬀect reactive aldehyde metabolism
and delay graft function. In particular, ~560 million people
in the world have a genetic variant of ALDH2, ALDH2∗2,
which severely limits the metabolism of reactive aldehydes
[26]. Although no study has associated with an ALDH2∗2
variant as a predictor of delayed graft function, this may
be due to organ transplantation (and in particular kidney
transplantation) numbers that are traditionally low in
East Asia compared to the rest of the world secondary
to cultural reasons [27]. Further, very little is known
regarding whether a genetic polymorphism in ALDH7A1
which decreases the enzymatic activity may also aﬀect
cellular function during organ transplantation. However,
ALDH7A1 overexpression protects from both cellular toxic-
ity and hyperosmotic stress [16, 28]. Therefore, the eﬀects
of either the donor or recipient having a genetic polymor-
phism in mitochondrial ALDH enzymes warrants further
study [7, 12].
Our study does have a number of potential limitations
that need to be considered when interpreting the data pre-
sented. Although we show an importance of reactive alde-
hyde production and metabolism in delayed graft function,
we could not conclusively identify all the enzymes involved
based on the size of the kidney biopsy obtained. Therefore,
we only focused on 3 ALDH enzymes even though AKR
and GSTA family members also had an increased gene
expression for kidneys that did not develop delayed graft
function. Additionally, the decreased protein expression
observed might also be due to loss of cell and mitochondrial
integrity since donor death itself induces metabolic dysregu-
lation and mitochondrial dysfunction. We also compared
grafts from living donor kidneys to deceased donor kidneys
that developed delayed graft function. Further studies will
be needed to compare reactive aldehyde production and
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Figure 5: Association of ALDH enzymatic activity with transplant outcomes. (a) The level of ALDH enzymatic activity measured from the
renal biopsy at 45 minutes after reperfusion during transplantation was associated with GFR at day 7 (GFR <10 n = 5, GFR 10-6 n = 3,
GFR >60 n = 8. ∗P = 0 013 versus >60 GFR group). (b) ALDH enzymatic activity was also negatively correlated with the length of hospital
stay. n = 16, ∗P = 0 0183.
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metabolism also in deceased donor kidneys that did not
develop delayed graft function as the eﬀect we identify may
be secondary to comparing living donor kidneys to deceased
donor kidneys.
The study is also an association study and will require
further validation both in experimental models and in the
clinical realm. Although we did ﬁnd associations for alde-
hyde enzymatic activity with GFR and length of hospital stay,
these associations should be considered with caution as many
factors contribute to the postoperative recovery from a
kidney transplant and a larger study would be important
to conﬁrm these ﬁndings.
Together, we suggest that a decreased ability to metabo-
lize reactive aldehydes in donor kidneys that develop delayed
graft function occurs (Figure 6). This diminished metabolism
of reactive aldehydes can result in aldehyde adducts forming
on proteins that can potentially impair cellular functions by
producing changes in enzyme activity, ion channel gating,
and mitochondrial energetics [7, 29–31].
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